Stomach (Gastric) Cancer Clinical Trial
Official title:
Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Stomach
Current therapies for Stomach Cancer provide very limited benefit to the patient. The
anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the
treatment of Stomach Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Stomach Cancer.
Stomach Cancer cancer patients receive gradually escalating doses of intravenous
Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached.
Treatment continues up to12 months in the absence of disease progression or unacceptable
toxicity.
OBJECTIVES:
- To determine the efficacy of Antineoplaston therapy in patients with Stomach Cancer, as
measured by an objective response to therapy (complete response, partial response or
stable disease).
- To determine the safety and tolerance of Antineoplaston therapy in patients with Stomach
Cancer.
- To determine objective response, tumor size is measured utilizing MRI scans, which are
performed every 8 weeks for the first two years, every 3 months for the third and fourth
years, every 6 months for the 5th and sixth years, and annually thereafter.
;